Bispecific Antibodies in Multiple Myeloma: Optimizing Care Across Settings

This AJMC Peer Exchange program brings together multiple myeloma experts to discuss the rapidly evolving role of bispecific antibodies across treatment settings. Panelists examine emerging clinical data, real world evidence, safety considerations, and practical strategies for integrating these therapies alongside CAR T-cell therapy and antibody drug conjugates. The discussion also highlights ongoing studies evaluating the potential use of bispecifics earlier in the treatment landscape, as well as opportunities to improve access, optimize sequencing, and support effective transitions between academic and community care.